TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9833847
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg abacavir twice daily
Study: 9833847
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg abacavir + zidovudine + lamivudine (open-label phase)
Study: 8135426
Drug: IV phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV phenytoin (15 mg/kg over 20 minutes)
Study: 28027625
Drug: Calcineurin Inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin Inhibitor (CNI) (n = 356)
Study: 19957560
Drug: Betaferon with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaferon with a reduced dosage regimen (2 MIU, 4 MIU, and 8 MIU) subcutaneously, varying by week (Group B)
Study: 16366421
Drug: HCA-SX 4,667
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCA-SX 4,667 mg (providing 2,800 mg HCA per day)
Study: 16366421
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HCA-SX 4,667 mg, niacin-bound chromium (NBC) 4 mg, and Gymnema sylvestre extract (GSE) 400 mg
Study: 7624991
Drug: Goserelin, 3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin, 3.6 mg every 28 days
Study: 16023214
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment for high-risk prethreshold ROP (n = 317 eyes)
Study: 16023214
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management when regression without treatment occurred
Study: 16023214
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment at high-risk prethreshold ROP with abnormal angle of temporal retinal vessels or macular ectopia
Study: 16023214
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment at high-risk prethreshold ROP with no retinal residua
Study: 11920310
Drug: high-dose IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose IFN
Study: 10334540
Drug: CDDP 50
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP 50 mg/m2, GEM 1,000 mg/m2, and VNR 25 mg/m2 on days 1 and 8 of an every-3-weeks cycle (arm A)
Study: 10334540
Drug: CDDP 80
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP 80 mg/m2, epirubicin 80 mg/m2, and vindesine 3 mg/m2 on day 1 every 4 weeks, plus lonidamine orally 150 mg three times daily (arm B)
Study: 10334540
Drug: CDDP-GEM-VNR combination
Normalized name: CDDP
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CDDP-GEM-VNR combination (arm A)
Study: 10334540
Drug: CDDP-epirubicin-vindesine-lonidamine combination
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP-epirubicin-vindesine-lonidamine combination (arm B)
Study: 1669483
Drug: 5 mg/ml
Normalized name: urea 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/ml (0.5%) timolol maleate
Study: 1669483
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (comparison group)
Study: 31529194
Drug: Prevena™ negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevena™ negative pressure wound therapy
Study: 31529194
Drug: PICO™ negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICO™ negative pressure wound therapy
Study: 9491788
Drug: oxaliplatin (L-OHP®)
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin (L-OHP®) in combination with continuous infusion 5-FU
Study: 7857999
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of weekly sessions of supervised group physical therapy
Study: 7857999
Drug: Unsupervised daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised daily exercises at home (discontinuation group)
Study: 2892520
Drug: Temazepam elixir
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Temazepam elixir 30 mg by mouth
Study: 2892520
Drug: Diazemuls i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazemuls i.v. titrated to a maximum dose of 20 mg
Study: 26187303
Drug: Mobile Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobile Insulin Titration Intervention (MITI) using SMS text messages and phone calls
Study: 26187303
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care arm (standard clinic care for insulin titration)
Study: 26187303
Drug: Mobile Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobile Insulin Titration Intervention (MITI)
Study: 6336975
Drug: Allopurinol pretreatment
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol pretreatment (300 mg two hours prior to and 10 hours after 5-FU)
Study: 6336975
Drug: Allopurinol pretreatment
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol pretreatment (300 mg every 8 hours for 4 doses starting 24 hours before 5-FU)
Study: 6336975
Drug: 5-FU administration
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU administration
Study: 23622444
Drug: Conventionally managed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally managed eyes (treatment only if threshold ROP developed)
Study: 20725062
Drug: EGCG (Teavigo)
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (Teavigo) 135 mg/capsule, 3 capsules/day for 48 hours
Study: 11733254
Drug: Dexamethasone eyedrops
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone eyedrops (0.1%) four times daily for 4 weeks (group A)
Study: 9441102
Drug: KRM 1648
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRM 1648 (KRM) at 20 micrograms/ml
Study: 9441102
Drug: Rifabutin (RBT)
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin (RBT) at 20 micrograms/ml
Study: 9441102
Drug: KRM 1648
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRM 1648 (KRM) at 0.2 microgram/ml combined with 2.0 micrograms/ml of CLA
Study: 9441102
Drug: Rifabutin (RBT)
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin (RBT) at 0.2 microgram/ml combined with 2.0 micrograms/ml of CLA
Study: 7950502
Drug: Ipriflavone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (600 mg/day, tdd) with 500 mg/day of calcium
Study: 2888551
Drug: Thyrotrophin binding
Normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin binding inhibiting (TBII) antibodies
Study: 2888551
Drug: Thyroid stimulating
Normalized name: Thyroid stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid stimulating (TSAb) antibodies
Study: 2888551
Drug: Thyroid growth
Normalized name: Thyroid growth-promoting immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid growth stimulating (TGI) antibodies
Study: 26292908
Drug: POCT urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: POCT urine culture and susceptibility testing and targeted treatment
Study: 26292908
Drug: POCT urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: POCT urine culture without susceptibility testing and empirical treatment
Study: 23811325
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment involving no sleep restriction but a fixed sleep schedule for older average sleepers.
Study: 21399490
Drug: Propofol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (4 mg · kg⁻¹ · h⁻¹)
Study: 16837678
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg on the first day, then 100 mg per day for four days)
Study: 9036434
Drug: 21-G pencil-point
Normalized name: ferric subsulfate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-G pencil-point needle (Sprotte)
Study: 9036434
Drug: 22-G Quincke
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-G Quincke needle
Study: 3887210
Drug: Platelet antiaggregant
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet antiaggregant therapy
Study: 7284544
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (not specified)
Study: 20081560
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for spinal stenosis
Study: 25365713
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for degenerative spondylolisthesis (DS)
Study: 25365713
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for intervertebral disc herniation (IDH)
Study: 25365713
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for degenerative spondylolisthesis (DS)
Study: 25365713
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for intervertebral disc herniation (IDH)
Study: 12222716
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam sedation
Study: 12222716
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam sedation
Study: 7734163
Drug: Prophylactic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic therapy with amoxicillin and clavulanic acid for 24 hours
Study: 7734163
Drug: Prophylactic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic therapy with amoxicillin and clavulanic acid for 5 days
Study: 7004556
Drug: Paracetamol/dextropropoxyphene combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/dextropropoxyphene combination
Study: 27015801
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 30 L/min
Study: 27015801
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy (LTOT) at 2‐4 L/min
Study: 18256366
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (blood pressure lowering regimen)
Study: 2643188
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 2 grams of ampicillin at the site of incision at closure
Study: 2643188
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical application of ampicillin
Study: 2643188
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ampicillin
Study: 377739
Drug: Aspirin 2.4
Normalized name: oxycodone/aspirin 2.44 mg-325 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 2.4 g daily
Study: 377739
Drug: Allopurinol 200
Normalized name: allopurinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 200 mg daily
Study: 24684456
Drug: Chewable tablet
Normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablet (TAB)
Study: 19120740
Drug: Interpersonal social
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal social rhythm therapy
Study: 15117896
Drug: Metformin (1.5-2.55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.5-2.55 g/day)
Study: 11985913
Drug: Beraprost sodium
Normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost sodium (median dose 80 microg four times a day)
Study: 7898228
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily (with triple therapy)
Study: 7898228
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy without omeprazole
Study: 27549867
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg daily for 24 weeks
Study: 27549867
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg daily for 24 weeks
Study: 23605225
Drug: Neurofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback treatment (30 sessions)
Study: 23605225
Drug: Usual maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual maintenance treatment (Methadone or Buprenorphine)
Study: 19626391
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (3 mg/kg and 10 mg/kg infliximab)
Study: 17605449
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure (heel preparation with no heel puncture)
Study: 30168731
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg acute dose)
Study: 30168731
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg/day for 4 weeks)
Study: 28031082
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose alendronate (70 mg per two weeks)
Study: 28031082
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose alendronate (70 mg weekly)
Study: 28031082
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose and standard dose alendronate
Study: 20685525
Drug: Extraction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction therapy (4 premolar extractions)
Study: 20685525
Drug: Nonextraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextraction treatment with air-rotor stripping (ARS)
Study: 17995982
Drug: PRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP plus intravitreal injection of 1.5 mg of bevacizumab
Study: 12813449
Drug: rhTPO 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO 1.5 microg/kg on days 1, 3, and 5 before G-CSF
Study: 12813449
Drug: rhTPO 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO 0.5 microg/kg on all 3 treatment days
Study: 12813449
Drug: rhTPO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO treatment
Study: 12813449
Drug: Placebo on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on days 1, 3, and 5 with G-CSF 5 microg/kg/day
Study: 7474048
Drug: Biofeedback (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback (with all treatment groups)
Study: 6755768
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg at 07h00, 13h00, and 19h00
Study: 26646464
Drug: Overall extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall extracorporeal membrane oxygenation therapy
Study: 23572490
Drug: Acetylcysteine 1200
Normalized name: acetylcysteine 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine 1200 mg
Study: 20617358
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) treatment for 24 weeks
Study: 2620952
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg succinylcholine
Study: 16368821
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg succinylcholine
Study: 16368821
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution (control group)
Study: 10678346
Drug: Lignocaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (10 mg) and methylprednisolone (40 mg) injection
Study: 10678346
Drug: Lignocaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (10 mg) injection only
Study: 3524471
Drug: Intralesional alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional alpha 2-interferon (IFN) 5 X 10(5) IU per dose, nine injections
Study: 3524471
Drug: Intralesional alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional alpha 2-interferon (IFN) 1 X 10(5) IU per injection
Study: 3524471
Drug: Intralesional alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional alpha 2-interferon (IFN) 1 X 10(4) IU per injection
Study: 3524471
Drug: Intralesional alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional alpha 2-interferon (IFN) 5 X 10(5) IU per injection, minimum of six injections
Study: 31679866
Drug: Zoster Vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster Vaccine Live (ZVL)
Study: 27778367
Drug: GR-MD-02 (galectin-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR-MD-02 (galectin-3 inhibitor)
Study: 21056263
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid (ZOL) 4 mg
Study: 17444041
Drug: PPV combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV combined with intravitreous antibiotic drugs
Study: 10215750
Drug: Ceftibuten (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (9 mg kg(‐1))
Study: 10215750
Drug: Cefixime (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (8 mg kg(‐1))
Study: 10215750
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg kg(‐1))
Study: 8885951
Drug: Low-dose indomethacin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose indomethacin
Study: 1950147
Drug: Cocktail group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail group (100 ml of fluorescein mixture)
Study: 1950147
Drug: Fraction group
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraction group (10 ml isolated fluorescein)
Study: 26121495
Drug: d-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: d-cycloserine (DCS) 50 mg
Study: 22779378
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education interventions (sample bag and/or video)
Study: 12447338
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen treatment
Study: 12479025
Drug: Seroxat 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seroxat 20 mg daily for four weeks
Study: 12479025
Drug: Post-treatment observation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment observation after stopping Seroxat
Study: 9805695
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl with 0.5% lidocaine (Group L + F) at doses of 0, 0.3, 1, 3, and 5 micrograms/kg
Study: 9805695
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl alone (Group F) at doses of 1, 3, and 5 micrograms/kg
Study: 7714348
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg controlled-release morphine sulfate tablet
Study: 7714348
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg controlled-release morphine sulfate tablet
Study: 1524367
Drug: 100 micrograms/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms/ml rPDGF-BB
Study: 31667483
Drug: Crocetin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocetin (10 mg per day)
Study: 22036839
Drug: ICP-targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-targeted therapy with CM monitoring
Study: 22036839
Drug: CPP-targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP-targeted therapy
Study: 22036839
Drug: ICP-targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-targeted therapy
Study: 19131241
Drug: Gastrazole by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrazole by continuous intravenous infusion
Study: 17994402
Drug: Levalbuterol HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol HFA 90 microg (two actuations of 45 microg) administered via metered dose inhaler (MDI) 30 minutes before exercise
Study: 17994402
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via metered dose inhaler (MDI) 30 minutes before exercise
Study: 12494136
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (all 4 main classes)
Study: 9876338
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily dose of DHEA for 6 months
Study: 10878680
Drug: Dexfenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (30 mg/day)
Study: 2536868
Drug: Adjuvant surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant surgical resection after chemotherapy
Study: 28235116
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy plus standard care (medical and nursing care with scheduled pharmacologic pain intervention)